- Home
- UTL vs ARVN Comparison
UTL vs ARVN Comparison
Compare UTL & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UTL | ARVN |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.9M | 740.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | UTL | ARVN |
|---|---|---|
| Price | $49.90 | $12.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 23 |
| Target Price | ★ $55.00 | $17.80 |
| AVG Volume (30 Days) | 122.2K | ★ 2.6M |
| Earning Date | 11-03-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.85 | N/A |
| Revenue | ★ $502,000,000.00 | $312,300,000.00 |
| Revenue This Year | $5.98 | N/A |
| Revenue Next Year | $7.76 | N/A |
| P/E Ratio | $17.51 | ★ N/A |
| Revenue Growth | 1.03 | ★ 93.86 |
| 52 Week Low | $44.61 | $5.90 |
| 52 Week High | $60.48 | $26.94 |
Technical Indicators
Market Signals| Indicator | UTL | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 62.74 | 59.94 |
| Support Level | $49.21 | $11.66 |
| Resistance Level | $51.00 | $12.62 |
| Average True Range (ATR) | 0.97 | 0.84 |
| MACD | 0.17 | 0.00 |
| Stochastic Oscillator | 79.34 | 51.91 |
Price Performance
Historical ComparisonAbout UTL UNITIL Corporation
Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. The Company has two operating and reportable segments: Utility Electric Operations and Utility Gas Operations. Majority of revenue is gained from Electric Segment.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.